Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010711 | 0.92 | PTGER4 (0.52) | PTGER4RORCMAPTKDM4EALDH1A1 | |
| SCHEMBL26452372 | 0.88 | PTGER4 (0.40) | PTGER4RORCKDM4E | |
| SCHEMBL17721923 | 0.85 | PTGER4 (0.38) | PTGER4RORCKDM4E | |
| SCHEMBL17721897 | 0.85 | PTGER4 (0.38) | PTGER4RORCKDM4E | |
| SCHEMBL18010701 | 0.85 | PTGER4 (0.52) | PTGER4RORCMAPTKDM4EALDH1A1 | |
| SCHEMBL29643208 | 0.85 | PTGER4 (0.63) | PTGER4RORCMAPTKDM4EALDH1A1 | |
| SCHEMBL5892136 | 0.85 | PTGER4 (0.63) | PTGER4RORCMAPTKDM4EALDH1A1 | |
| SCHEMBL18540331 | 0.84 | KDM4E (0.45) | PTGER4RORCKDM4E | |
| SCHEMBL18540338 | 0.84 | KDM4E (0.45) | PTGER4RORCKDM4E | |
| SCHEMBL15250630 | 0.84 | ATM (0.47) | PTGER4RORCKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3061759-B1 | NITRILE SUBSTITUTED DIBENZOFURANS | IDEMITSU KOSAN CO (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-20190305228-A1 | ORGANIC LIGHTEMITTING COMPOUND HAVING PHOSPHORESCENT CHARACTERISTIC AT ROOM TEMPERATURE, AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DEVICE INCLUDING THE ORGANIC LIGHTEMITTING COMPOUND | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) | 2019-10-03 | — | — | US | disclosed |
| EP-3061759-A1 | NITRILE SUBSTITUTED DIBENZOFURANS | Idemitsu Kosan Co., Ltd (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20160248026-A1 | NITRILE SUBSTITUTED DIBENZOFURANS | IDEMITSU KOSAN CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160087224-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160087227-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190305228-A1 | ORGANIC LIGHTEMITTING COMPOUND HAVING PHOSPHORESCENT CHARACTERISTIC AT ROOM TEMPERATURE, AND PHOSPHORESCENT ORGANIC LIGHT EMITTING DEVICE INCLUDING THE ORGANIC LIGHTEMITTING COMPOUND | MAP1LC3C, MAP1LC3A, MAP1LC3B | PTGER4 2603/4885RORC 410/4885MAPT 494/4885 |
| US-20160248026-A1 | NITRILE SUBSTITUTED DIBENZOFURANS | DBF4, NXF1, NCF1 | PTGER4 1001/4885RORC 4100/4885MAPT 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.